GlassScriptPhysician profile
Arthur L Ostrowski
NPI 1740257062
$10,910.64
in general payments reported to CMS, 2019-2025
21 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $1,500 · 2021: $1,704 · 2022: $1,126 · 2023: $1,651 · 2024: $1,094 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,765.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,281.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,464.66 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $887.20 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $769.62 | 2019-2023 | |
| Novo Nordisk INC | $750.33 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $451.36 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $355.37 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.23 | 2019-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $173.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $163.24 | 2023-2025 | |
| Allergan, INC. | $156.26 | 2020 | |
| Sanofi-Aventis U.S. LLC | $121.82 | 2019 | |
| Vertiflex, INC. | $109.86 | 2019 | |
| Esperion Therapeutics, INC. | $28.26 | 2020-2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.56 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $22.21 | 2021 | |
| Abbvie INC. | $18.83 | 2025 | |
| Astellas Pharma US INC | $17.05 | 2023 | Veozah |
| Actelion Pharmaceuticals US, INC. | $15.62 | 2023 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $14.34 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.